Opinion|Videos|November 18, 2026

Detecting MET-Driven Resistance and the SAFFRON Survival Data

Ticiana Leal, MD, of Winship Cancer Institute of Emory University, reviews the phase 3 SAFFRON trial, presented at the European Society for Medical Oncology Congress 2026, which compared osimertinib plus savolitinib with platinum-based chemotherapy in EGFR-mutant, MET-overexpressed or MET-amplified non–small cell lung cancer after progression on osimertinib.

Ticiana Leal, MD, of Winship Cancer Institute of Emory University, reviews the phase 3 SAFFRON trial, presented at the European Society for Medical Oncology Congress 2026, which compared osimertinib plus savolitinib with platinum-based chemotherapy in EGFR-mutant, MET-overexpressed or MET-amplified non–small cell lung cancer after progression on osimertinib. The combination improved progression-free survival and overall survival, with a median overall survival of 17.8 vs 12.9 months, which she says addresses an important gap and strengthens the case for repeating next-generation sequencing at progression. Julia Rotow, MD, of Dana-Farber Cancer Institute, explains that MET remains the most common actionable resistance mechanism and can be detected as protein overexpression by immunohistochemistry or as amplification by next-generation sequencing or fluorescence in situ hybridization, populations that overlapped only partly in SAFFRON. Prescreening in SACHI, INSIGHT, and SAFFRON each found MET positivity in about one-third of patients. Both agree tissue is needed, because liquid biopsy cannot detect overexpression.


Related to this article